<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cardiovascular risks of hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cardiovascular risks of hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cardiovascular risks of hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Bloch, MD, FACP, FASH, FSVM, FNLA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jan Basile, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In terms of population-attributable risk, hypertension is the most important modifiable risk factor for premature cardiovascular disease [<a href="#rid1">1</a>]; it is more common than cigarette smoking, dyslipidemia, and diabetes, which are the other major risk factors  (<a class="graphic graphic_table graphicRef81993" href="/d/graphic/81993.html" rel="external">table 1</a>). Hypertension accounts for an estimated 54 percent of all strokes and 47 percent of all ischemic heart disease events globally [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p>The impact of hypertension on the risk for cardiovascular disorders and the impact of cardiovascular risk on therapeutic decisions in the treatment of hypertension are discussed in this topic. The effects of different antihypertensive drugs and of different blood pressure goals on cardiovascular outcomes are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p></p><p class="headingAnchor" id="H2992205647"><span class="h1">IMPACT OF HYPERTENSION ON CARDIOVASCULAR DISEASE</span><span class="headingEndMark"> — </span>Hypertension increases the risk for a variety of cardiovascular diseases [<a href="#rid3">3-5</a>], including stroke, coronary artery disease, heart failure, atrial fibrillation [<a href="#rid6">6</a>], abdominal aortic aneurysm, and peripheral vascular disease. In a large electronic medical record cohort of 1.25 million patients, those with hypertension had a higher lifetime risk of cardiovascular disease than those without high blood pressure (63 versus 46 percent) and, on average, developed cardiovascular disease five years earlier [<a href="#rid4">4</a>].</p><p>The risk for both coronary disease and stroke increases progressively with incremental increases in blood pressure above 115/75 mmHg, as shown in numerous epidemiologic studies  (<a class="graphic graphic_figure graphicRef75106 graphicRef66793" href="/d/graphic/75106.html" rel="external">figure 1A-B</a>) [<a href="#rid7">7-13</a>]. For each 20/10 mmHg increase in systolic/diastolic blood pressure, there is a doubling of coronary heart- and stroke-related mortality. However, these observations do not prove a causal relationship, since increasing blood pressure could be a marker for other risk factors such as increasing body weight, which is associated with dyslipidemia, glucose intolerance, and the metabolic syndrome. The best evidence for a causal role of increasing blood pressure in cardiovascular complications is an improvement in outcome as blood pressure is reduced with antihypertensive therapy [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p>The increase in cardiovascular risk has primarily been described in terms of elevated systolic pressure in older adults [<a href="#rid15">15</a>] and elevation in both systolic and diastolic pressure in younger individuals. Pulse pressure, which is the difference between the systolic and diastolic blood pressures and is determined primarily by large artery stiffness, is also a strong predictor of risk, particularly in older individuals [<a href="#rid15">15</a>]. Conversely, isolated diastolic hypertension, in which the diastolic pressure is elevated but the systolic pressure is normal, is uncommon in the adult and not associated with a higher cardiovascular risk [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/3858.html" rel="external">"Increased pulse pressure"</a>.)</p><p>Out-of-office blood pressure measurements may predict cardiovascular risk better than routine clinic measurements, a fact that has led to increased reliance upon home and ambulatory blood pressure monitoring (ABPM) to make the diagnosis of hypertension [<a href="#rid5">5,17</a>]. These issues are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Making the diagnosis of hypertension'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring"</a>.)</p><p></p><p class="headingAnchor" id="H2275201410"><span class="h2">Impact of hypertension on specific cardiovascular disorders</span><span class="headingEndMark"> — </span>The magnitude of the association between hypertension and cardiovascular disease varies according to the specific cardiovascular outcome. In one large cohort study, for example, hypertension (which was defined as a blood pressure ≥140/90 mmHg) increased the relative risk of stroke (by 3.8 and 2.6 in males and females, respectively). In addition, heart failure was increased (by 4.0 and 3.0 in males and females, respectively) and to a greater degree than the relative risk of coronary heart disease (by 2.0 and 2.2, respectively) [<a href="#rid18">18</a>].</p><p>Projections have been made for the expected decrease in morbidity and mortality with pharmacologic antihypertensive therapy by using data from 48 randomized trials performed over the past 50 years [<a href="#rid19">19</a>]. Based upon this meta-analysis, a 5 mmHg reduction in blood pressure, maintained over a mean of about four years, would approximately translate into a 10 percent reduction in major cardiovascular events, including a 13 percent reduction in stroke, an 8 percent reduction in ischemic heart disease, a 13 percent reduction in incident heart failure, and a 5 percent reduction in cardiovascular death [<a href="#rid19">19</a>]. These estimated relative risk reductions are independent of preexisting cardiovascular disease or initial blood pressure level (including in those with normal blood pressure). A previous meta-analysis of 123 studies of pharmacologic antihypertensive therapy found that a 10 mmHg reduction in blood pressure reduced the relative risk of coronary heart disease by 17 percent, stroke by 27 percent, heart failure by 28 percent, and all-cause mortality by 13 percent [<a href="#rid20">20</a>]. In both analyses, despite similar relative risk reductions, absolute benefits of blood pressure lowering were greater among those with higher baseline cardiovascular risk and higher baseline blood pressure.</p><p>As noted above, the best evidence for a causal role of increasing blood pressure in cardiovascular complications is an improvement in outcome as blood pressure is reduced with antihypertensive therapy [<a href="#rid14">14,19</a>]. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p class="headingAnchor" id="H2"><span class="h2">Additive effects of hypertension and other risk factors</span><span class="headingEndMark"> — </span>The different cardiovascular risk factors have an additive effect on the likelihood of developing coronary heart disease and other cardiovascular outcomes [<a href="#rid21">21,22</a>]. In addition to hypertension, the major risk factors are older age, elevated total and low-density lipoprotein (LDL) cholesterol, a low high-density lipoprotein (HDL) cholesterol, diabetes mellitus, and cigarette smoking. Thus, individual patients who have significant hypertension but none or few of the other risk factors are at relatively lower overall risk than patients with less hypertension but more of the other risk factors  (<a class="graphic graphic_figure graphicRef55353" href="/d/graphic/55353.html" rel="external">figure 2</a>) [<a href="#rid21">21,23</a>]. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p>Multiple risk prediction models using these and other risk factors have been developed, most notably the Framingham risk score [<a href="#rid21">21,22</a>]. The ability of the Framingham risk criteria to predict cardiovascular disease has been widely reproduced [<a href="#rid24">24-26</a>], but the degree of cardiovascular risk related to the Framingham risk criteria may not apply to all patient populations [<a href="#rid27">27-29</a>]. Other risk factors have been proposed to improve upon the Framingham risk assessment, including C-reactive protein, brain natriuretic peptide, echocardiography, and other studies for detecting subclinical vascular disease [<a href="#rid30">30-32</a>]. However, none have been proven to add significantly to the Framingham scoring, and they are probably not cost effective.</p><p>Other risk prediction models exist, including one developed by the American Heart Association (AHA) and the American College of Cardiology (ACC) that incorporated data from multiple patient cohorts and includes risk of all cardiovascular events, including stroke, rather than coronary heart disease alone (<a class="calc calc_professional" href="/d/html/107063.html" rel="external">calculator 1</a>) [<a href="#rid33">33</a>].</p><p>A detailed discussion on estimation of cardiovascular risk in an individual without known disease is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">APPLICATION OF RISK ASSESSMENT TO THERAPEUTIC DECISIONS</span></p><p class="headingAnchor" id="H2389367633"><span class="h2">Use of baseline cardiovascular risk to guide treatment decisions</span><span class="headingEndMark"> — </span>A central question in the care of hypertensive patients is whether or not treatment decisions (eg, use of antihypertensive medications, goal blood pressure) should be applied uniformly to the entire hypertensive population or, instead, tailored according to a patient's risk for future cardiovascular events. The benefit a patient receives from blood pressure lowering depends upon the balance between the <strong>absolute</strong> (rather than relative) reduction in risk for adverse outcomes and the potential harms and burdens of antihypertensive therapy. (See  <a class="medical medical_review" href="/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a> and  <a class="medical medical_review" href="/d/html/114029.html" rel="external">"Cardiovascular disease risk assessment for primary prevention: Risk calculators"</a>.)</p><p>Although the relative cardiovascular risk reduction appears to be the same regardless of the baseline cardiovascular risk, the absolute number of cardiovascular events prevented by therapy is significantly greater in the population with higher baseline cardiovascular risk. This concept is presented in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p>A group from New Zealand, for example, took various cardiovascular risk factors into account in determining the overall risk status of individual patients, including their level of blood pressure, age, gender, and other factors  (<a class="graphic graphic_figure graphicRef55353" href="/d/graphic/55353.html" rel="external">figure 2</a>) [<a href="#rid23">23</a>]. They then examined the evidence of benefits of antihypertensive therapy from the clinical trials and considered the costs of such therapy. They concluded that antihypertensive therapy could be justified only if the risk for a major cardiovascular event over the next five years was 10 percent or greater or if the level of blood pressure was so high as to mandate therapy regardless of overall risk status (≥170/100 mmHg).</p><p>Several professional organizations have recommended that markers of overall cardiovascular risk be incorporated in treatment decisions [<a href="#rid34">34-36</a>]. As an example, guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) suggest initiating hypertensive medications in higher-risk individuals at lower blood pressures than those with lower overall cardiovascular risk [<a href="#rid5">5</a>]. Details of our approach are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Current risk versus prior risk</span><span class="headingEndMark"> — </span>In addition to the specific patient population [<a href="#rid27">27</a>], another problem with the use of such data is that the risk status that is currently assessed may not reflect what was previously present. This is an important issue because it is the <strong>prior</strong> risk status that is more likely to be responsible for the current health of the individual.</p><p>As an example, although blood pressure at the time of risk assessment (current blood pressure) is typically used in most prediction algorithms, this does not accurately reflect an individual's past blood pressure experience; the use of long-term, average blood pressure is more accurate. This is supported by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 3560 individuals, the presence of elevated blood pressure before age 35 years was associated with coronary calcification (which is a strong predictor of future coronary heart disease) later in life. This association was observed after adjusting for blood pressure and other coronary risk factors that were present after age 35 years [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A report from the Framingham Heart Study found that recent and remote antecedent blood pressure (systolic, diastolic, and pulse pressure) predicted cardiovascular risk incrementally over current blood pressure [<a href="#rid38">38</a>]. This effect was seen in males and females, younger and older individuals, and lower and higher blood pressure groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, 1604 males whose risk status was first assessed when they were aged 45 to 64 years and free of clinically obvious cardiovascular disease were then reassessed 25 years later when they were aged 70 to 90 years [<a href="#rid39">39</a>]. Most patients changed their risk status over this time period, moving forward or backward. When the current risk status of the 342 subjects who developed cardiovascular disease (myocardial infarction, angina, coronary bypass surgery, angioplasty, or stroke) during the follow-up period was compared with that of the 279 who remained healthy, there were few differences. However, the results were different when the original risk status was used. Those patients who remained healthy had significantly lower blood pressure (121/79 versus 134/83 mmHg) and plasma cholesterol levels (211 versus 226 mg/dL [5.45 versus 5.84 mmol/L]) 25 years before.</p><p></p><p>Based upon these data, clinicians need to be cautious about only using current cardiovascular risk estimates to predict subsequent events [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H28449520"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4416.html" rel="external">"Patient education: High blood pressure in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4424.html" rel="external">"Patient education: High blood pressure treatment in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>In terms of population-attributable risk, hypertension is the most significant risk factor for premature cardiovascular disease; it is more important than cigarette smoking, dyslipidemia, and diabetes, which are the other major risk factors  (<a class="graphic graphic_table graphicRef81993" href="/d/graphic/81993.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension increases the risk for a variety of cardiovascular diseases, including stroke, coronary artery disease, heart failure, atrial fibrillation, abdominal aortic aneurysm, and peripheral vascular disease. The risk for both coronary disease and stroke increases progressively with incremental increases in blood pressure above 115/75 mmHg, as shown in numerous epidemiologic studies  (<a class="graphic graphic_figure graphicRef75106 graphicRef66793" href="/d/graphic/75106.html" rel="external">figure 1A-B</a>). However, the best evidence for a causal role of increasing blood pressure in cardiovascular complications is an improvement in outcome with antihypertensive therapy. (See <a class="local">'Impact of hypertension on cardiovascular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The magnitude of the association between hypertension and cardiovascular disease varies according to the specific cardiovascular outcome. Using data from multiple studies, a 5 and 10 mmHg reduction in systolic pressure is projected to produce a 10 and 20 percent relative risk reduction in major cardiovascular events, respectively, including significant reductions in risk of stroke, coronary disease, heart failure, and cardiovascular death. (See <a class="local">'Impact of hypertension on specific cardiovascular disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The different cardiovascular risk factors have an additive effect on the likelihood of developing coronary heart disease and other cardiovascular outcomes. Multiple risk prediction models using these and other risk factors have been developed, including one developed by the American Heart Association (AHA) and the American College of Cardiology (ACC) that incorporated data from multiple patient cohorts and includes risk of all cardiovascular events, including stroke, rather than coronary heart disease alone (<a class="calc calc_professional" href="/d/html/107063.html" rel="external">calculator 1</a>). (See <a class="local">'Additive effects of hypertension and other risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The benefit a patient receives from blood pressure lowering depends upon the balance between the <strong>absolute</strong> (rather than relative) reduction in risk for adverse outcomes and the potential harms and burdens of antihypertensive therapy. We, and several professional organizations, recommend that markers of overall cardiovascular risk be incorporated in treatment decisions. (See <a class="local">'Application of risk assessment to therapeutic decisions'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392:1923.</a></li><li><a class="nounderline abstract_t">Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371:1513.</a></li><li><a class="nounderline abstract_t">Flint AC, Conell C, Ren X, et al. Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes. N Engl J Med 2019; 381:243.</a></li><li><a class="nounderline abstract_t">Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383:1899.</a></li><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.</a></li><li><a class="nounderline abstract_t">Angeli F, Reboldi G, Verdecchia P. Hypertension, inflammation and atrial fibrillation. J Hypertens 2014; 32:480.</a></li><li><a class="nounderline abstract_t">Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.</a></li><li><a class="nounderline abstract_t">Son JS, Choi S, Kim K, et al. Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events. JAMA 2018; 320:1783.</a></li><li><a class="nounderline abstract_t">Yano Y, Reis JP, Colangelo LA, et al. Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life. JAMA 2018; 320:1774.</a></li><li><a class="nounderline abstract_t">Pastor-Barriuso R, Banegas JR, Damián J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139:731.</a></li><li><a class="nounderline abstract_t">Pletcher MJ, Bibbins-Domingo K, Lewis CE, et al. Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med 2008; 149:91.</a></li><li><a class="nounderline abstract_t">Shen L, Ma H, Xiang MX, Wang JA. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease. Am J Cardiol 2013; 112:266.</a></li><li><a class="nounderline abstract_t">Clarke R, Wright N, Walters R, et al. Genetically Predicted Differences in Systolic Blood Pressure and Risk of Cardiovascular and Noncardiovascular Diseases: A Mendelian Randomization Study in Chinese Adults. Hypertension 2023; 80:566.</a></li><li><a class="nounderline abstract_t">Blood Pressure Lowering Treatment Trialists' Collaboration, Ninomiya T, Perkovic V, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013; 347:f5680.</a></li><li><a class="nounderline abstract_t">Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865.</a></li><li><a class="nounderline abstract_t">McEvoy JW, Daya N, Rahman F, et al. Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA 2020; 323:329.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2021; 325:1650.</a></li><li><a class="nounderline abstract_t">Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275:1571.</a></li><li><a class="nounderline abstract_t">Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021; 397:1625.</a></li><li><a class="nounderline abstract_t">Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387:957.</a></li><li><a class="nounderline abstract_t">Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7:7S.</a></li><li><a class="nounderline abstract_t">Kannel WB, Wolf PA. Framingham Study insights on the hazards of elevated blood pressure. JAMA 2008; 300:2545.</a></li><li><a class="nounderline abstract_t">Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365:434.</a></li><li><a class="nounderline abstract_t">Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294:466.</a></li><li><a class="nounderline abstract_t">Frost PH, Davis BR, Burlando AJ, et al. Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program. Circulation 1996; 94:26.</a></li><li><a class="nounderline abstract_t">Lowe LP, Greenland P, Ruth KJ, et al. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998; 158:2007.</a></li><li><a class="nounderline abstract_t">Bastuji-Garin S, Deverly A, Moyse D, et al. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens 2002; 20:1973.</a></li><li><a class="nounderline abstract_t">Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987.</a></li><li><a class="nounderline abstract_t">Zambon A, Arfè A, Corrao G, Zanchetti A. Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment: an aid to definition of total cardiovascular disease risk in hypertension. J Hypertens 2014; 32:495.</a></li><li><a class="nounderline abstract_t">Simon A, Chironi G, Levenson J. Performance of subclinical arterial disease detection as a screening test for coronary heart disease. Hypertension 2006; 48:392.</a></li><li><a class="nounderline abstract_t">Olsen MH, Wachtell K, Nielsen OW, et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. J Hypertens 2006; 24:1531.</a></li><li><a class="nounderline abstract_t">Cuspidi C, Meani S, Valerio C, et al. Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens 2006; 24:1671.</a></li><li><a class="nounderline abstract_t">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1.</a></li><li><a class="nounderline abstract_t">Task Force for the management of arterial hypertension of the European Society of Hypertension, Task Force for the management of arterial hypertension of the European Society of Cardiology. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. Blood Press 2013; 22:193.</a></li><li><a class="nounderline abstract_t">Gabb GM, Mangoni AA, Anderson CS, et al. Guideline for the diagnosis and management of hypertension in adults - 2016. Med J Aust 2016; 205:85.</a></li><li><a class="nounderline abstract_t">Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol 2016; 32:569.</a></li><li><a class="nounderline abstract_t">Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48:833.</a></li><li><a class="nounderline abstract_t">Vasan RS, Massaro JM, Wilson PW, et al. Antecedent blood pressure and risk of cardiovascular disease: the Framingham Heart Study . Circulation 2002; 105:48.</a></li><li><a class="nounderline abstract_t">Benfante R, Hwang LJ, Masaki K, Curb JD. To what extent do cardiovascular risk factor values measured in elderly men represent their midlife values measured 25 years earlier? A preliminary report and commentary from the Honolulu Heart Program. Am J Epidemiol 1994; 140:206.</a></li></ol></div><div id="topicVersionRevision">Topic 3850 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30496105" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456100" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Global burden of blood-pressure-related disease, 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314968" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24881994" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477094" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hypertension, inflammation and atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12493255" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30398603" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30398601" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14597457" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626048" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prehypertension during young adulthood and coronary calcium later in life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23608614" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36601918" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genetically Predicted Differences in Systolic Blood Pressure and Risk of Cardiovascular and Noncardiovascular Diseases: A Mendelian Randomization Study in Chinese Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092942" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10752701" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990314" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33904861" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622248" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Blood pressure as a cardiovascular risk factor: prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33933205" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26724178" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7946184" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Established risk factors and coronary artery disease: the Framingham Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050198" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Framingham Study insights on the hazards of elevated blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15680460" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16046653" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hypertension in adults across the age spectrum: current outcomes and control in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964114" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Coronary heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778200" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12359975" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Framingham prediction rule is not valid in a European population of treated hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788299" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24378997" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment: an aid to definition of total cardiovascular disease risk in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16880350" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Performance of subclinical arterial disease detection as a screening test for coronary heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877955" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877972" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222016" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23777479" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27456450" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Guideline for the diagnosis and management of hypertension in adults - 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118291" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904557" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11772875" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antecedent blood pressure and risk of cardiovascular disease: the Framingham Heart Study .</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8030624" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : To what extent do cardiovascular risk factor values measured in elderly men represent their midlife values measured 25 years earlier? A preliminary report and commentary from the Honolulu Heart Program.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
